Results 321 to 330 of about 95,583 (387)

Implantable cardioverter‐defibrillators in ischaemic versus non‐ischaemic heart failure: Insights from the VICTORIA trial

open access: yesEuropean Journal of Heart Failure, EarlyView.
Mode of death stratified by implantable cardioverter‐defibrillator (ICD) status. CI, confidence interval; CV, cardiovascular; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HR, hazard ratio; SCD, sudden cardiac death. Abstract Aims Guidelines recommend the use of implantable cardioverter‐defibrillators (ICDs) to reduce the risk
Pishoy Gouda   +11 more
wiley   +1 more source

Sex‐based differences in heart failure management and outcomes: Insights from the French‐DataHF cohort

open access: yesEuropean Journal of Heart Failure, EarlyView.
Sex differences in heart failure (HF) management and outcomes in the French‐DataHF cohort. CI, confidence interval; HFH, heart failure hospitalization; HR, hazard ratio; IPW, inverse probability weighting; KM, Kaplan–Meier; LD, loop diuretic; RAS, renin–angiotensin system; RASi, renin–angiotensin system inhibitor.
Guillaume Baudry   +7 more
wiley   +1 more source

Hyperbaric Oxygen Regulates Tumor pH to Boost Copper‐Doped Hydroxyethyl Starch Conjugate Nanoparticles Against Cancer Stem Cells

open access: yesExploration, EarlyView.
Hypoxia and acidic microenvironments are characteristic features of solid tumors, driving tumor growth, drug resistance, and metastasis. To address these issues, we combined hyperbaric oxygen therapy with rational designed hydroxyethyl starch‐doxorubicin‐copper nanoparticles to modulate the acidic microenvironment of tumors while enhancing the efficacy
Qingyuan Deng   +9 more
wiley   +1 more source

Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type 2 diabetes. [PDF]

open access: yesCardiovasc Diabetol
Chaiyakunapruk N   +5 more
europepmc   +1 more source

Evaluating Guideline Alignment by Analyzing Patient Profiles of Elderly People with Type 2 Diabetes and Chronic Kidney Disease Treated or Not with SGLT2 Inhibitors. [PDF]

open access: yesPharmaceuticals (Basel)
Vafeidou K   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy